We are live on
!
Find out more
PVAM
Pacific View Asset Management Portfolio holdings
AUM
$20.8M
1-Year Est. Return
20.08%
This Fund
S&P 500
This Quarter
Est. Return
+19.99%
1 Year Est. Return
+20.08%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$96.3M
AUM Growth
+$11.2M
(+13%)
Cap. Flow
-$150K
Cap. Flow
% of AUM
-0.16%
Top 10 Holdings %
Top 10 Hldgs %
54.39%
Holding
61
New
6
Increased
24
Reduced
18
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$5.53M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$4.33M |
| 3 |
EFOR
Everforth Inc
EFOR
|
+$1.66M |
| 4 |
Ameris Bancorp
ABCB
|
+$1.64M |
| 5 |
ABM Industries
ABM
|
+$1.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$3.05M |
| 2 |
PFPT
Proofpoint, Inc.
PFPT
|
+$3.01M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$2.33M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$2.33M |
| 5 |
Granite Construction
GVA
|
+$1.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.35% |
| 2 | Industrials | 19.7% |
| 3 | Financials | 17.34% |
| 4 | Technology | 9.34% |
| 5 | Consumer Staples | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Supernus Pharmaceuticals
SUPN
$2.7B
| $252K | 0.26% |
+7,208
| New | +$268K |
|
52
AnaptysBio
ANAB
$1.54B
| $214K | 0.22% |
+2,925
| New | +$202K |
|
53
Silicon Laboratories
SLAB
$7.14B
| $213K | 0.22% |
2,608
| – | – |
|
54
Healthcare Services Group
HCSG
$1.61B
| – | – |
-6,956
| Closed | -$280K |
|
55
HubSpot
HUBS
$12.9B
| – | – |
-5,257
| Closed | -$661K |
|
56
Lumentum
LITE
$46.9B
| – | – |
-7,008
| Closed | -$295K |
|
|
NEWR
57
DELISTED
New Relic, Inc.
NEWR
| – | – |
-12,393
| Closed | -$1M |
|
|
SPPI
58
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| – | – |
-69,143
| Closed | -$605K |
|
|
PFPT
59
DELISTED
Proofpoint, Inc.
PFPT
| – | – |
-35,904
| Closed | -$3.01M |
|
|
LOXO
60
DELISTED
Loxo Oncology, Inc
LOXO
| – | – |
-21,775
| Closed | -$3.05M |
|
|
EVOL
61
DELISTED
Evolving Systems, Inc.
EVOL
| – | – |
-438,637
| Closed | -$520K |
|
Similar funds
CIM
ICP
QI
HWM
AGU
PCP
MAU
FCG
Pacific View Asset Management's Q1 2019 Portfolio in Review
As of Q1 2019, Pacific View Asset Management held 61 positions worth $96.3M, up 13% from $85.1M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Pacific View Asset Management's Q1 2019 filing shows 6 new, 24 increased, 18 reduced and 8 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 50,601 shares worth $5.66M. The largest sale was Loxo Oncology, Inc, an estimated $3.05M.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 14% a quarter earlier, followed by Industrials and Financials.
- Pacific View Asset Management's largest Q1 2019 buy was Intercept Pharmaceuticals, Inc.: 50,601 shares worth $5.66M.
- Pacific View Asset Management added most to Sage Therapeutics in Q1 2019, an estimated $4.33M increase.
- Pacific View Asset Management's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $2.33M.
- Pacific View Asset Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $3.05M.
- Pacific View Asset Management's ten largest holdings make up 54% of its $96.3M portfolio in Q1 2019.
- Pacific View Asset Management opened 6 new positions and closed 8 in Q1 2019.
- Pacific View Asset Management's portfolio value rose 13% quarter-over-quarter to $96.3M.
Based on Pacific View Asset Management's 13F filing for Q1 2019, filed 15 May 2019.